AU2009211159B2 - Process for preparing bosentan - Google Patents

Process for preparing bosentan Download PDF

Info

Publication number
AU2009211159B2
AU2009211159B2 AU2009211159A AU2009211159A AU2009211159B2 AU 2009211159 B2 AU2009211159 B2 AU 2009211159B2 AU 2009211159 A AU2009211159 A AU 2009211159A AU 2009211159 A AU2009211159 A AU 2009211159A AU 2009211159 B2 AU2009211159 B2 AU 2009211159B2
Authority
AU
Australia
Prior art keywords
compound
formula
process according
bosentan
ethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009211159A
Other languages
English (en)
Other versions
AU2009211159A1 (en
Inventor
Abhay Gaitonde
Hemant Mande
Bindu Manojkumar
Sandeep Mekde
Vikas Padalkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009211159(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of AU2009211159A1 publication Critical patent/AU2009211159A1/en
Application granted granted Critical
Publication of AU2009211159B2 publication Critical patent/AU2009211159B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2009211159A 2008-02-08 2009-02-06 Process for preparing bosentan Ceased AU2009211159B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN228/KOL/2008 2008-02-08
IN228KO2008 2008-02-08
PCT/GB2009/050120 WO2009098517A1 (en) 2008-02-08 2009-02-06 Process for preparing bosentan

Publications (2)

Publication Number Publication Date
AU2009211159A1 AU2009211159A1 (en) 2009-08-13
AU2009211159B2 true AU2009211159B2 (en) 2013-02-07

Family

ID=40467334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009211159A Ceased AU2009211159B2 (en) 2008-02-08 2009-02-06 Process for preparing bosentan

Country Status (10)

Country Link
US (1) US8785461B2 (cg-RX-API-DMAC10.html)
EP (1) EP2245018B1 (cg-RX-API-DMAC10.html)
JP (1) JP5683276B2 (cg-RX-API-DMAC10.html)
CN (1) CN101939301B (cg-RX-API-DMAC10.html)
AU (1) AU2009211159B2 (cg-RX-API-DMAC10.html)
CA (1) CA2712860C (cg-RX-API-DMAC10.html)
ES (1) ES2650247T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ587793A (cg-RX-API-DMAC10.html)
PT (1) PT2245018T (cg-RX-API-DMAC10.html)
WO (1) WO2009098517A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8530488B2 (en) 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
WO2013098577A1 (en) * 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of bosentan
CN104487057A (zh) * 2012-05-11 2015-04-01 韩诺生物制药株式会社 波生坦控释口服制剂
CN112457259B (zh) * 2020-12-08 2024-02-20 重庆康乐制药有限公司 一种磺胺多辛的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743307B1 (en) * 1995-05-16 2001-09-12 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
SI1535613T1 (sl) 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
HUP0204069A3 (en) 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
PT1254121E (pt) 2000-01-25 2006-06-30 Hoffmann La Roche Preparacao de sulfonamidas
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
AU2003209669A1 (en) 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
WO2004087660A1 (en) 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
AU2006248593B2 (en) 2005-05-17 2011-03-17 Actelion Pharmaceuticals Ltd. Dispersible bosertan tablet
US20080188663A1 (en) 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
BRPI0809171A2 (pt) 2007-04-02 2014-09-16 Auspex Pharmaceuticals Inc "composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina"
WO2008135795A2 (en) 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
EP2205591A1 (en) 2007-10-11 2010-07-14 Actavis Group PTC EHF Novel polymorphs of bosentan
US8530488B2 (en) 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
ATE530531T1 (de) * 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
WO2009112954A2 (en) 2008-03-13 2009-09-17 Actavis Group Ptc Ehf Processes for the preparation of bosentan and related compounds using novel intermediates
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
IT1393136B1 (it) 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743307B1 (en) * 1995-05-16 2001-09-12 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same

Also Published As

Publication number Publication date
CN101939301B (zh) 2016-07-06
CN101939301A (zh) 2011-01-05
CA2712860A1 (en) 2009-08-13
AU2009211159A1 (en) 2009-08-13
US20110039871A1 (en) 2011-02-17
EP2245018A1 (en) 2010-11-03
PT2245018T (pt) 2017-12-05
CA2712860C (en) 2014-11-18
JP2011511054A (ja) 2011-04-07
NZ587793A (en) 2012-06-29
EP2245018B1 (en) 2017-08-30
US8785461B2 (en) 2014-07-22
WO2009098517A1 (en) 2009-08-13
JP5683276B2 (ja) 2015-03-11
ES2650247T3 (es) 2018-01-17

Similar Documents

Publication Publication Date Title
AU2008272685B2 (en) Process for introduction of hydroxyethoxy side chain in bosentan
CA2712860C (en) Process for preparing bosentan
AU2008247169B2 (en) Polymorphic forms of bosentan
KR20100113542A (ko) 보센탄, 그의 결정다형 형태 및 그의 염의 합성 방법
EP1673351A1 (en) A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
JP2008539278A (ja) 結晶性ロスバスタチンカルシウム
US20150218126A1 (en) Crystalline forms of thalidomide and processes for their preparation
KR20090113920A (ko) 로수바스타틴의 부분입체 이성질체 정제
JP2012523444A (ja) 内皮受容体アンタゴニスト（ボセンタン）を調製するための方法
WO2020168144A1 (en) Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(lh)- isoquinolinyl)ethyl] phenyl }-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl] -4- oxo-4h-chromene-2-carboxamide and of its mesylate salt
CA2619576C (en) Crystalline rosuvastatin intermediate
AU2003268213A1 (en) Crystalline solid famciclovir forms i, ii, iii and preparation thereof
EP2332923A1 (en) 5-ý2-(methylthio)ethoxy¨pyrimidine-2-amine manufacturing method
KR20070030948A (ko) 템포 매개의 산화 단계를 포함하는 로수바스타틴의 제조방법
JPH0149691B2 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired